ECSP12012004A - Método de tratamiento de la fibrilación auricular - Google Patents
Método de tratamiento de la fibrilación auricularInfo
- Publication number
- ECSP12012004A ECSP12012004A ECSP12012004A ECSP12012004A EC SP12012004 A ECSP12012004 A EC SP12012004A EC SP12012004 A ECSP12012004 A EC SP12012004A EC SP12012004 A ECSP12012004 A EC SP12012004A
- Authority
- EC
- Ecuador
- Prior art keywords
- treatment
- fibrilation
- headphone
- atrial
- salts
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 206010003662 Atrial flutter Diseases 0.000 abstract 1
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002084 dronedarone Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960000213 ranolazine Drugs 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método para el tratamiento o la prevención de la fibrilación auricular y/o el aleteo auricular que comprende la coadministración de una cantidad sinérgicamente terapéutica de dronedarona o una sal o sales farmacéuticamente aceptables de la misma y una cantidad sinérgicamente terapéutica de ranolazina o una sal o sales farmacéuticamente aceptables de la misma. También se proporcionan métodos para modular la frecuencia y el ritmo ventricular y auricular. Esta invención también se refiere a formulaciones farmacéuticas que son adecuadas para tal administración combinada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28873909P | 2009-12-21 | 2009-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12012004A true ECSP12012004A (es) | 2012-08-31 |
Family
ID=43736345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12012004 ECSP12012004A (es) | 2009-12-21 | 2012-06-27 | Método de tratamiento de la fibrilación auricular |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US8513254B2 (es) |
| EP (2) | EP2515900B1 (es) |
| JP (2) | JP5723889B2 (es) |
| KR (2) | KR20120107995A (es) |
| CN (3) | CN102665713B (es) |
| AP (1) | AP3536A (es) |
| AR (1) | AR079552A1 (es) |
| AU (1) | AU2010339753B2 (es) |
| BR (1) | BR112012015499A2 (es) |
| CA (1) | CA2784028C (es) |
| CL (1) | CL2012001597A1 (es) |
| CR (1) | CR20120353A (es) |
| CY (1) | CY1116511T1 (es) |
| DK (1) | DK2515900T3 (es) |
| EA (2) | EA201691336A1 (es) |
| EC (1) | ECSP12012004A (es) |
| ES (2) | ES2540093T3 (es) |
| HR (1) | HRP20150644T1 (es) |
| HU (1) | HUE026916T2 (es) |
| IL (1) | IL220152A (es) |
| ME (1) | ME02179B (es) |
| MX (2) | MX2012007052A (es) |
| NO (1) | NO2749282T3 (es) |
| NZ (2) | NZ600718A (es) |
| PE (1) | PE20121520A1 (es) |
| PL (2) | PL2515900T3 (es) |
| PT (2) | PT2515900E (es) |
| RS (1) | RS54118B1 (es) |
| SG (3) | SG181541A1 (es) |
| SI (2) | SI2515900T1 (es) |
| SM (1) | SMT201500171B (es) |
| TW (1) | TWI508726B (es) |
| UA (1) | UA109887C2 (es) |
| UY (1) | UY33119A (es) |
| WO (1) | WO2011084733A1 (es) |
| ZA (1) | ZA201204608B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003248558B8 (en) | 2002-05-21 | 2009-07-09 | Gilead Sciences, Inc. | Method of treating diabetes |
| HUE034911T2 (hu) | 2009-07-27 | 2018-03-28 | Gilead Sciences Inc | Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok |
| CN102724946B (zh) | 2009-07-29 | 2015-06-10 | Icu医学有限公司 | 流体传输装置及使用方法 |
| WO2011135582A2 (en) * | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Pharmaceutical compositions of dronedarone |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2012154760A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| JP2015504923A (ja) * | 2012-01-27 | 2015-02-16 | ギリアード サイエンシーズ， インコーポレイテッド | 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法 |
| WO2014179764A1 (en) * | 2013-05-03 | 2014-11-06 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
| WO2015017441A1 (en) * | 2013-08-02 | 2015-02-05 | Gilead Sciences, Inc. | Pharmaceutical compositions of ranolazine and dronedarone |
| WO2015073922A2 (en) | 2013-11-15 | 2015-05-21 | Northwestern University | Inhibition of oxidative stress in atrial fibrillation |
| WO2015095370A1 (en) | 2013-12-19 | 2015-06-25 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| CN104951870B (zh) * | 2015-06-01 | 2018-11-13 | 南通科瑞斯生物医药科技有限公司 | 药物临床前心脏风险评估方法 |
| WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| JP2019510752A (ja) | 2016-03-04 | 2019-04-18 | ギリアード サイエンシーズ， インコーポレイテッド | オートタキシン阻害剤の組成物及び合剤 |
| US10575744B2 (en) | 2017-02-24 | 2020-03-03 | Medtronic Cryocath Lp | Pericardial balloon mapping |
| US10799703B2 (en) * | 2017-12-22 | 2020-10-13 | Medtronic, Inc. | Evaluation of his bundle pacing therapy |
| EP3530182B1 (en) * | 2018-02-27 | 2020-12-09 | Nokia Technologies Oy | Apparatus and method for determining a change in left ventricular twist of a subject's heart |
| CA3103522C (en) | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| EP3914709A4 (en) * | 2019-01-24 | 2023-05-03 | Northwestern University | Gene therapy treatment of atrial fibrillation |
| US11712188B2 (en) * | 2019-05-07 | 2023-08-01 | Medtronic, Inc. | Posterior left bundle branch engagement |
| KR20250171439A (ko) | 2019-08-01 | 2025-12-08 | 인카다 테라퓨틱스, 인크. | 항부정맥 제제 |
| AU2022403012B2 (en) | 2021-12-03 | 2026-02-12 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| FI4440702T3 (fi) | 2021-12-03 | 2025-08-08 | Gilead Sciences Inc | Terapeuttisia yhdisteitä hiv-virusinfektiota varten |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| ES2177601T3 (es) | 1989-06-23 | 2002-12-16 | Syntex Llc | Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. . |
| FR2665444B1 (fr) | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
| US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
| FR2764800B1 (fr) | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
| US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| ATE357257T1 (de) * | 2000-07-27 | 2007-04-15 | Pharmacia Corp | Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen |
| FR2817750B1 (fr) | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
| AU2002231175A1 (en) | 2000-12-27 | 2002-07-08 | Focal, Inc. | Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart |
| CA2453587A1 (en) * | 2001-07-20 | 2003-02-06 | Karo Bio Ab | Benzofuranes and their use in the treatment of atrial fibrillation |
| US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
| MX2007008162A (es) | 2005-01-06 | 2007-07-24 | Cv Therapeutics Inc | Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina. |
| WO2007053610A2 (en) | 2005-11-01 | 2007-05-10 | The Regents Of The University Of California | Methods of treating atrial fibrillation wtih pirfenidone |
| CA2678272A1 (en) | 2007-02-13 | 2008-10-02 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| EP2133074A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
| JP2012502047A (ja) | 2008-09-04 | 2012-01-26 | ギリアード サイエンシーズ， インコーポレイテッド | 心房細動を治療する方法 |
-
2010
- 2010-12-16 TW TW099144230A patent/TWI508726B/zh not_active IP Right Cessation
- 2010-12-20 EP EP20100798436 patent/EP2515900B1/en active Active
- 2010-12-20 DK DK10798436.1T patent/DK2515900T3/en active
- 2010-12-20 JP JP2012544937A patent/JP5723889B2/ja active Active
- 2010-12-20 SG SG2012041638A patent/SG181541A1/en unknown
- 2010-12-20 UY UY33119A patent/UY33119A/es not_active Application Discontinuation
- 2010-12-20 CN CN201080058336.3A patent/CN102665713B/zh not_active Expired - Fee Related
- 2010-12-20 AP AP2012006331A patent/AP3536A/xx active
- 2010-12-20 CN CN201410377525.7A patent/CN104147010A/zh active Pending
- 2010-12-20 ES ES10798436.1T patent/ES2540093T3/es active Active
- 2010-12-20 BR BR112012015499A patent/BR112012015499A2/pt not_active IP Right Cessation
- 2010-12-20 SG SG10201710751TA patent/SG10201710751TA/en unknown
- 2010-12-20 KR KR1020127018477A patent/KR20120107995A/ko not_active Ceased
- 2010-12-20 PL PL10798436T patent/PL2515900T3/pl unknown
- 2010-12-20 EP EP14161300.0A patent/EP2749282B1/en active Active
- 2010-12-20 MX MX2012007052A patent/MX2012007052A/es active IP Right Grant
- 2010-12-20 MX MX2014002642A patent/MX344329B/es unknown
- 2010-12-20 CA CA2784028A patent/CA2784028C/en not_active Expired - Fee Related
- 2010-12-20 SG SG10201408528RA patent/SG10201408528RA/en unknown
- 2010-12-20 SI SI201030949T patent/SI2515900T1/sl unknown
- 2010-12-20 KR KR1020167024642A patent/KR20160108611A/ko not_active Ceased
- 2010-12-20 NZ NZ600718A patent/NZ600718A/en not_active IP Right Cessation
- 2010-12-20 HR HRP20150644TT patent/HRP20150644T1/hr unknown
- 2010-12-20 NZ NZ627181A patent/NZ627181A/en not_active IP Right Cessation
- 2010-12-20 EA EA201691336A patent/EA201691336A1/ru unknown
- 2010-12-20 PT PT107984361T patent/PT2515900E/pt unknown
- 2010-12-20 EA EA201290451A patent/EA025445B1/ru not_active IP Right Cessation
- 2010-12-20 ME MEP-2015-113A patent/ME02179B/me unknown
- 2010-12-20 AU AU2010339753A patent/AU2010339753B2/en not_active Ceased
- 2010-12-20 RS RS20150489A patent/RS54118B1/sr unknown
- 2010-12-20 AR ARP100104774A patent/AR079552A1/es unknown
- 2010-12-20 HU HUE10798436A patent/HUE026916T2/en unknown
- 2010-12-20 NO NO14161300A patent/NO2749282T3/no unknown
- 2010-12-20 UA UAA201208208A patent/UA109887C2/uk unknown
- 2010-12-20 WO PCT/US2010/061257 patent/WO2011084733A1/en not_active Ceased
- 2010-12-20 CN CN201510028705.9A patent/CN104688739A/zh active Pending
- 2010-12-20 PE PE2012000852A patent/PE20121520A1/es active IP Right Grant
- 2010-12-20 SI SI201031571T patent/SI2749282T1/sl unknown
- 2010-12-20 ES ES14161300.0T patent/ES2646603T3/es active Active
- 2010-12-20 PL PL14161300T patent/PL2749282T3/pl unknown
- 2010-12-20 PT PT141613000T patent/PT2749282T/pt unknown
- 2010-12-20 US US12/972,949 patent/US8513254B2/en not_active Expired - Fee Related
-
2012
- 2012-06-04 IL IL220152A patent/IL220152A/en not_active IP Right Cessation
- 2012-06-14 CL CL2012001597A patent/CL2012001597A1/es unknown
- 2012-06-21 ZA ZA2012/04608A patent/ZA201204608B/en unknown
- 2012-06-27 CR CR20120353A patent/CR20120353A/es not_active Application Discontinuation
- 2012-06-27 EC ECSP12012004 patent/ECSP12012004A/es unknown
-
2013
- 2013-05-31 US US13/907,349 patent/US8754087B2/en not_active Expired - Fee Related
-
2014
- 2014-03-20 US US14/221,014 patent/US9056108B2/en not_active Expired - Fee Related
- 2014-12-22 JP JP2014258433A patent/JP2015057449A/ja not_active Withdrawn
-
2015
- 2015-07-14 SM SM201500171T patent/SMT201500171B/xx unknown
- 2015-07-17 CY CY20151100625T patent/CY1116511T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012002A (es) | Compuesto heterocíclico conteniendo nitrógeno y fungicida para el uso en agricultura y jardinería | |
| MX344329B (es) | Formulación de una combinación de dronedarona y ranolazina para la manufactura de un medicamento para tratar fibrilación atrial. | |
| CY1117440T1 (el) | Συτηκτα παραγωγα ιμιδαζολης ως αναστολεις toy ido | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| EP4684836A3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| NZ630589A (en) | Methods of treating alzheimer’s disease and pharmaceutical compositions thereof | |
| WO2016004093A3 (en) | Therapeutic compositions including galectin-3 inhibitors and uses thereof | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| PE20170302A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| AR087177A1 (es) | Formulacion de una capsula que comprende montelukast y levocetirizina | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| MX346730B (es) | Composiciones y metodos para el tratamiento de la hipertension pulmonar. | |
| WO2010028173A3 (en) | Method of treating atrial fibrillation | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| BR112019002945A2 (pt) | terapia de combinação para o tratamento de câncer pancreático | |
| JOP20190086A1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
| WO2015183985A3 (en) | Therapeutic compositions including naphthoquinones and uses thereof | |
| CY1120669T1 (el) | Συνδυαστικη θεραπεια για αγωγη σκληρυνσης κατα πλακας | |
| NO20064196L (no) | Utvortes preparat for behandling av smertefulle hudskader | |
| TH141448A (th) | สูตรตำรับทางเภสัชกรรมประกอบด้วยราโนราซีนและโดรนิดาโรนเพื่อการรักษาการเต้นแผ่วระรัวของหัวใจห้องบน | |
| NZ780408A (en) | Human plasma kallikrein inhibitors | |
| ECSP109996A (es) | Composición farmacéutica que comprende la combinación de un agente antimicrobiano y un agente inhibidor selectivo de la enzima encefalinasa, indicada para el control y tratamiento de la diarrea aguda de origen bacteriano | |
| PL406970A1 (pl) | Zastosowanie mieszaniny tiosemikarbazonu 2-karbaldehydu-3-aminopirydyny z fotouczulaczem do wytwarzania kompozycji farmaceutycznej przeznaczonej do stosowania w przeciwnowotworowej terapii fotodynamicznej |